Clin Pediatr Hematol Oncol.  2017 Oct;24(2):148-152. 10.15264/cpho.2017.24.2.148.

A Case of Pediatric Precursor B-cell Acute Lymphoblastic Leukemia Associated with Translocations (14;18)(q32;q21) and (8;9)(q24;p13)

Affiliations
  • 1Department of Pediatrics, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea. jjseo@amc.seoul.kr
  • 2Genetic Medical Center, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea.
  • 3Department of Laboratory Medicine, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea.

Abstract

Precursor B-cell acute lymphoblastic leukemia (ALL), which is the most common subtype of pediatric acute leukemia, generally has a good prognosis. However, the prognosis also depends on the genetic abnormalities of the leukemic blast. Concurrent MYC and IGH/BCL2 translocations have recently been reported as a "double hit" in adult patients, but non-immunoglobulin (non-IG)/MYC translocation has rarely been reported. In this paper, we report a case of pediatric precursor B-cell ALL associated with translocations (14;18)(q32;q21) and (8;9)(q24;p13). The patient was a previously healthy 13-year-old boy. Complete remission was not achieved after first-line four-drug induction chemotherapy; thus, intensive salvage regimen, including high-dose cytarabine and L-asparaginase, were administered, which resulted in morphologic remission. However, his disease relapsed during the second cycle of salvage regimen, and he died of sepsis-induced multiorgan failure.

Keyword

Pediatric; Precursor B-cell lymphoblastic leukemia; Translocations; MYC; BCL2

MeSH Terms

Adolescent
Adult
Cytarabine
Humans
Induction Chemotherapy
Leukemia
Male
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma
Precursor Cell Lymphoblastic Leukemia-Lymphoma*
Precursor Cells, B-Lymphoid*
Prognosis
Cytarabine
Full Text Links
  • CPHO
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2022 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr